Besides, researchers suggested that the tumor cells harboring ARID1A alterations showed the therapeutic sensitivity to Bcl-2 inhibitors which indicated the activation of apoptotic pathways induced by ARID1A alterations or expression loss. This evidence concerns the gene BCL2 and neoplasm.